Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

[1]  P. Richardson,et al.  Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Sara M. Federico,et al.  Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB). , 2017 .

[3]  Günter Schreier,et al.  Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[4]  A. Naranjo,et al.  A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. , 2016 .

[5]  Sara M. Federico,et al.  Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study. , 2016 .

[6]  S. Servaes,et al.  Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children’s Oncology Group (COG). , 2016 .

[7]  A. Seif,et al.  Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma , 2016, Bone Marrow Transplantation.

[8]  P. Blanchard,et al.  Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution , 2016, Bone Marrow Transplantation.

[9]  L. Lehmann,et al.  Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers , 2016, Pediatric transplantation.

[10]  B. Yalçın,et al.  High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. , 2015, The Cochrane database of systematic reviews.

[11]  C. Pui,et al.  Natural killer cell therapy in children with relapsed leukemia , 2015, Pediatric blood & cancer.

[12]  I. Ostrovnaya,et al.  Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study , 2015, Oncoimmunology.

[13]  S. Servaes,et al.  A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study. , 2015 .

[14]  W. Furman,et al.  Comparison of pain outcomes between two anti‐GD2 antibodies in patients with neuroblastoma , 2015, Pediatric blood & cancer.

[15]  C. Pui,et al.  Rapid Memory T-cell Reconstitution Recapitulating CD45RA-depleted Haploidentical Transplant Graft Content in Patients with Hematologic Malignancies , 2015, Bone Marrow Transplantation.

[16]  W. Leung.  Infusions of Allogeneic Natural Killer Cells as Cancer Therapy , 2014, Clinical Cancer Research.

[17]  KyungMann Kim,et al.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Pai,et al.  Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high‐risk neuroblastoma: Early results from a single institution , 2014, Pediatric transplantation.

[19]  J. Maris,et al.  Children's Oncology Group's 2013 blueprint for research: Neuroblastoma , 2013, Pediatric blood & cancer.

[20]  A. Naranjo,et al.  Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Á. Lassaletta,et al.  High-Dose Busulfan and Melphalan as Conditioning Regimen for Autologous Peripheral Blood Progenitor Cell Transplantation in High-Risk Neuroblastoma Patients , 2011, Pediatric hematology and oncology.

[22]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[23]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[24]  L. Sorkin,et al.  Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia , 2010, PAIN®.

[25]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Koo,et al.  Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome , 2008, Bone Marrow Transplantation.

[27]  M. Lindorfer,et al.  Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving1 , 2008, The Journal of Immunology.

[28]  F. Ghiringhelli,et al.  Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity , 2008, Cancer Immunology, Immunotherapy.

[29]  Y. Lau,et al.  Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.

[30]  John M Maris,et al.  The biologic basis for neuroblastoma heterogeneity and risk stratification , 2005, Current opinion in pediatrics.

[31]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[32]  R. Handgretinger,et al.  Purification of human natural killer cells using a clinical-scale immunomagnetic method. , 2003, Cytotherapy.

[33]  F. Pastorino,et al.  Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. , 2003, Cancer letters.

[34]  A. Mcmillan,et al.  Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma , 2002, Bone Marrow Transplantation.

[35]  P. Suess,et al.  Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment , 2002, Bone Marrow Transplantation.

[36]  G. Vassal,et al.  Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma , 2000, Bone Marrow Transplantation.

[37]  E. Carreras.  Veno‐occlusive disease of the liver after hemopoietic cell transplantation , 2000, European journal of haematology.

[38]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[39]  S. Schwartz,et al.  Suppression of human natural and antibody-dependent cytotoxicity by soluble factors from unstimulated normal lymphocytes. , 1982, Journal of immunology.

[40]  C. Pui,et al.  Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies , 2015, Bone Marrow Transplantation.

[41]  S. Grupp,et al.  Neuroblastoma: issues in transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[43]  A. Yu,et al.  Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. , 1991, Cancer research.